Document text
Principal Investigator: Megan A O'Connor
Organization: UNIVERSITY OF WASHINGTON
Fiscal Year: 2024
Award: $353,000
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY/ABSTRACT
COVID-19 vaccination is safe, immunogenic, and durable in individuals with treated and virally suppressed HIV
infection but is less immunogenic in immunosuppressed individuals and those with unsuppressed HIV infection.
The rollout of COVID-19 vaccines is still limited in countries with high HIV prevalence and low access to
antiretroviral therapy (ART), necessary to suppress HIV viral replication and reduce HIV-associated
comorbidities. Thus, studying COVID-19 vaccination in immunosuppressed and untreated HIV populations is
needed. We generated an Alphavirus-derived replicon RNA (repRNA) SARS-CoV-2 vaccine candidate, repRNA-
CoV2S, encoding the SARS-CoV-2 spike protein and delivered by a novel Lipid InOrganic Nanoparticle (LION),
a cationic nanoemulsion (CNE). This vaccine platform generates robust and durable protective immunity against
SARS-CoV-2 infection in mice and nonhuman primates. Preliminary studies indicate this vaccine is immunogenic
in non-human primates with HIV-induced immunosuppression and those with B-cell deficiencies, demonstrating
that a repRNA-CoV2S vaccine could be employed to induce strong immunity against COVID-19 in
immunosuppressed individuals living with HIV. Here, in a highly relevant pre-clinical SIV macaque model for HIV
infection, we will test a 2nd generation COVID-19 vaccine, repRNA- Omicron, that 1) encodes the SARS-CoV-2
Omicron S protein and 2) is comprised of a novel chimeric immunogen (SHARP) which focuses immune
responses to the receptor binding domain (RBD) and promotes neutralizing antibodies. We will evaluate the
immunogenicity and durability of repRNA-Omicron during untreated SIV-associated immunosuppression and
examine the role of SIV-induced immune activation and exhaustion on vaccine immune memory. Furthermore,
our studies will aim to understand the mechanisms driving humoral memory by the novel repRNA/LION vaccine
platform. If successful, this work will further contribute to understanding the mechanisms driving SARS-CoV-2
vaccine breakthrough infections and reinfections in people living with HIV and will inform improved treatment
and vaccine strategies for people living with HIV and other immunocompromised individuals.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><AIDS Virus><AIDS/HIV><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Alpha Virus><Anabolism><Animals><Antigens><Automobile Driving><B blood cells><B cell><B cells><B-Cell Deficiency><B-Cells><B-Lymphocytes><B-cell><B.1.1.529><Booster Immunization><Bp35><CAR T cell therapy><CAR T therapy><CD20><CD4 Lymphocyte Count><CD4+ Cell Counts><CD4+ Counts><COVID-19><COVID-19 S protein><COVID-19 immunity><COVID-19 infection><COVID-19 related risk><COVID-19 risk><COVID-19 risk factor><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccination><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID19 infection><COVID19 virus><CV-19><Cancers><Cell Body><Cells><Cessation of life><CoV-2><CoV2><Coronavirus Infectious Disease 2019><Country><Data><Death><Development><Diabetes Mellitus><Disease><Disorder><Dose><Early-Stage Clinical Trials><Evaluation><Exclusion><Formulation><Frequencies><Generations><Germinal Center><Goals><Group A Arboviruses><HIV><HIV Infections><HIV/AIDS><HTLV-III Infections><HTLV-III-LAV Infections><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><Hospital Admission><Hospitalization><Human><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Immune Cell Activation><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune System Diseases><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immune memory><Immune response><Immunity><Immunization><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunodeficiency and Immunosuppression Disorders><Immunologic Diseases><Immunologic Factors><Immunologic Memory><Immunological Diseases><Immunological Dysfunction><Immunological Factors><Immunological Memory><Immunological System Dysfunction><Immunological response><Immunosuppressed Host><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Impaired Driving><Impairment><Individual><Inducer Cells><Inducer T-Lymphocytes><Infection><Influenza HA><Influenza Hemagglutinin><LAV-HTLV-III><Leu-16><Lipids><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Lymphadenopathy-Associated Virus><M nemestrina><M. nemestrina><MS4A1><MS4A1 gene><MS4A2><Macaca><Macaca nemestrina><Macaque><Malignant Neoplasms><Malignant Tumor><Measures><Memory><Messenger RNA><Methods><Mice><Mice Mammals><Modeling><Modern Man><Murine><Mus><Non-Polyadenylated RNA><Omicron variant><Persons><Phase 1 Clinical Trials><Phase I Clinical Trials><Pigtail Macaque><Pigtail Monkey><Population><Prevalence><Proteins><Public Health><RNA><RNA Gene Products><RNA replication><RNA vaccine><RNA-based vaccine><Regulatory T-Lymphocyte><Replication Unit><Replicon><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-limited setting><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><Ribonucleic Acid><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.1.529><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 immunity><SARS-CoV-2 infection><SARS-CoV-2 omicron><SARS-CoV-2 omicron variant><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SIV><Secondary Immunization><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Simian Immunodeficiency Viruses><Structure of germinal center of lymph node><T-Cells><T-Lymphocyte><T4 Lymphocyte Count><Testing><Treg><Vaccines><Viral><Virus Replication><Virus-HIV><Work><Wuhan coronavirus><access to vaccination><access to vaccines><anamnestic reaction><antiretroviral therapy><antiretroviral treatment><biosynthesis><booster vaccination><breakthrough infection><cardiovascular disease risk><cardiovascular disorder risk><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor T cell therapy><chimeric antigen receptor T therapy><co-morbid><co-morbidity><comorbidity><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 immunity><coronavirus disease 2019 infection><coronavirus disease 2019 risk><coronavirus disease 2019 risk factor><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><cytokine><deliver vaccines><developmental><diabetes><driving><driving while impaired><exhaustion><flu HA><flu hemagglutinin><hCoV19><host response><humoral immunity deficiency><immune activation><immune response to vaccination><immune response to vaccines><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immunity against COVID-19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunogen><immunogenic><immunogenicity><immunologic substance><immunological substance><immunoresponse><immunosuppressed><immunosuppressed patient><immunosuppressive activity><immunosuppressive function><immunosuppressive response><impaired driving performance><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><influenza viral HA><influenza viral hemagglutinin><influenza virus HA><influenza virus hemagglutinin><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA lipid nano particle vaccine><mRNA vaccine><mRNA-LNP based vaccine><mRNA-LNP combination vaccines><mRNA-LNP vaccines><mRNA-based vaccine><malignancy><mortality><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><nano emulsion><nano particle><nano-sized particle><nanoemulsion><nanoparticle><nanosized particle><neoplasm/cancer><neutralizing antibody><non-human primate><nonhuman primate><novel><omicron variant of COVID-19><omicron variant of SARS-CoV-2><phase I protocol><pig-tailed macaque><pre-clinical><preclinical><receptor binding><receptor bound><regulatory T-cells><response><risk associated with COVID-19><risk factor associated with COVID-19><risk factor related to COVID-19><risk related to COVID-19><secondary immune response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.1.529><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><social role><spike proteins on SARS-CoV-2><thymus derived lymphocyte><treatment strategy><vaccinate against COVID-19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination access><vaccination against COVID-19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccination availability><vaccination study><vaccination trial><vaccine access><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine associated immune response><vaccine availability><vaccine candidate><vaccine candidates against SARS-CoV-2><vaccine delivery><vaccine for novel coronavirus><vaccine immune response><vaccine immunogenicity><vaccine induced immune response><vaccine platform><vaccine strategy><vaccine study><vaccine trial><vaccines preventing COVID><vaccines to prevent COVID><variants of concern><viral multiplication><viral replication><virus multiplication>